Company intelligence / Profile preview

Wisp

Ownership: Private
Employees: ~75
Development stage: Commercial

Overview

Wisp has served over 1.2 million patients nationwide with positive EBITDA since 2021. The company offers same-day prescriptions, at-home diagnostic testing for STIs and other conditions, and recently expanded into menopause care, fertility services, GLP‑1-based weight management solutions, and more. It operates on a cash-pay model without insurance requirements[2][3][7].

Therapeutic areas: Women's HealthEndocrinologyInfectious Diseases
Modalities: Small moleculeHormoneBiologic
Industry: Non-Academic Healthcare

Partnerships

Partnered CLIA/CAP-accredited laboratories for diagnostics

Beyond the preview

Go deeper on Wisp.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wisp.

Explore the full profile